Elasmogen exploits its unique soloMER™ technology as drugs in small, simple, and stable formats that are amenable to site-specific and systemic delivery.
Elasmogen is progressing life-extending therapies for those patients that have been let down by current small molecule and systemic monoclonal antibody approaches.